Chemotherapy + Stem Cell Transplant for Lymphoma

Recruiting in Palo Alto (17 mi)

+125 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Alliance for Clinical Trials in Oncology

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The purpose of this study is to find out what effects (good and/or bad) treatment with chemotherapy and stem cell transplant compared with chemotherapy alone will have on primary CNS B-cell lymphoma. Currently the best treatment for patients with primary CNS B-cell lymphoma is not known.

Research Team

Tracy Batchelor, MD, MPH

Principal Investigator

Massachusetts General Hospital

Eligibility Criteria

This trial is for adults aged 18-75 with primary CNS B-cell lymphoma, no history of other non-Hodgkin lymphomas or prior treatments. Participants must have a Karnofsky score indicating they can care for themselves and not be pregnant or nursing. They should test negative for HIV, hepatitis, and agree to use effective contraception.

Inclusion Criteria

I am mostly independent but may need assistance for some daily activities.

My diagnosis of brain lymphoma was confirmed through a biopsy or fluid tests.

I have not had chemotherapy or radiation for lymphoma.

See 7 more

Treatment Details

Interventions

Autologous Stem Cell Transplant (Other)
Carmustine (Alkylating agents)
Cytarabine (Alkylating agents)
Thiotepa (Alkylating agents)

Trial OverviewThe study compares the effects of chemotherapy alone versus chemotherapy followed by an autologous stem cell transplant in treating central nervous system B-cell lymphoma. The goal is to determine which treatment approach is more beneficial.

Participant Groups

2Treatment groups

Experimental Treatment

Group I: Arm IIExperimental Treatment3 Interventions

Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo consolidation chemotherapy.

Group II: Arm IExperimental Treatment4 Interventions

Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo stem cell transplant.

Carmustine is already approved in Canada for the following indications: